Reports

Reports
Karolinska Institute Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
33

“Karolinska Institute - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Karolinska Institute. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There is 1 cancer drugs by Karolinska Institute which is commercially available in the market. The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data

Reports
Kyowa Hakko Kirin Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
181

“Kyowa Hakko Kirin - Cancer Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Kyowa Hakko Kirin. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “33” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 11 cancer drugs by Kyowa Hakko Kirin which are commercially available in the market. The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying

Reports
Leo Pharma Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
27

“Leo Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Leo Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “3” cancer drugs in clinical pipeline.The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development

Reports
MabVax Therapeutics Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
25

“MabVax Therapeutics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by MabVax Therapeutics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in preclinical phase.The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status

Reports
Taiho Pharmaceutical Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
68

“Taiho Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Taiho Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I. There are 7 cancer drugs by Taiho Pharmaceutical which are commercially available in the market. The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and

Reports
Immunomedics Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
84

“Immunomedics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Immunomedics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in preclinical phase.The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction

Reports
Jiangsu Hengrui Medicine co Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
30

“Jiangsu Hengrui Medicine Co. - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Jiangsu Hengrui Medicine Co. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in phase-I. There is 1 cancer drug by Jiangsu Hengrui Medicine Co. which is commercially available in the market. The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the

Reports
Idera Pharmaceutical Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
35

“Idera Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Idera Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “6” cancer drugs in clinical pipeline and majority of them are in preclincal phase.The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status

Reports
Introgen Therapeutics Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
33

“Introgen Therapeutics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Introgen Therapeutics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline.The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development

Reports
Shire Cancer Drugs Clinical Pipeline Insight
Published
Number of pages
75

“Shire - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Shire. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “19” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 5 cancer drugs by Shire which are commercially available in the market. The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points